Global /Taiwan /Healthcare /Biotechnology /6986

HeXun Biosciences Co., Ltd.

6986

• TPEX: 6986 • Delayed

62.10TWD -2.1%

1.96 USD

As of 21 June 2026, HeXun Biosciences Co., Ltd. has a market cap of $92.23M USD, ranking #26115 globally and #1444 in Taiwan. It ranks #2340 in the Healthcare sector, and #451 in the Biotechnology industry.

Global Rank

26115

Country Rank

1444

Sector Rank

2340

Industry Rank

451

Key Stats

Market Cap

$92.23MUSD

2.92B TWD

Enterprise Value

$77.22MUSD

2.44B TWD

Revenue (TTM)

$9.27MUSD

293.23M TWD

EBITDA (TTM)

$4.48MUSD

141.68M TWD

Net Income (TTM)

$3.54MUSD

111.91M TWD

EBITDA Margin

48%

Profit Margin

38%

PE Ratio

26.1

PS Ratio

9.9

PB Ratio

3.9

EV/EBITDA

16.7

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Ji-Hong Huang open_in_new

Employees

Founded

2019

Website

hexunbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	-4.2%	3.7%	5.2%	8%	-1.1%	-19%	-35%	-35%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6986 和迅生命科學股份有限公司 ISIN: TW0006986003 Shares Out.: Shares Outstanding: 46.0M¹ TV: TradingView: TPEX: 6986 SA: Stock Analysis: TPEX: 6986 YF: Yahoo Finance: 6986.TWO GF: Google Finance: TPEX: 6986 BA: Barron's: 6986 MS: Morningstar: ROCO: 6986	62.10 TWD	TV: TradingView: TPEX: 6986 SA: Stock Analysis: TPEX: 6986 YF: Yahoo Finance: 6986.TWO GF: Google Finance: TPEX: 6986 BA: Barron's: 6986 MS: Morningstar: ROCO: 6986

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About HeXun Biosciences Co., Ltd.

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 6K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 2K%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 1K%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 687%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 551%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 519%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 198K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 173K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 51K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 48K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 46K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 45K%	37.2	Switzerland

chevron_leftBack